Skip to content

US · NEPH · MEDICAL - INSTRUMENTS & SUPPLIES

Nephros, Inc. (NEPH) intrinsic value and stock valuation

$2.61as of 2026-11-21 · Mkt cap 38.87M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Nephros, Inc. DCF and intrinsic value

InvestorsCraft values NEPH with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NEPH’s statements →

Nephros, Inc. Graham Number

Graham Number: $1.56d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies South Orange, NJ 07079 nephros.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$18.8M+17% 5y CAGRd
20112025
Net income
$1.19M
20112025
Free cash flow
$1.65M
20112025
Total equity
$10.2M-8.1% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$18.8M$14.2M$14.2M$9.97M$10.2M
Operating income$1.15M$10K-$-1.59M-$-4.33M-$-3.25M
Net income$1.19M$70K-$-1.57M-$-7.38M-$-4.11M
EPSd$108.5K$6.6K-$-151.11K-$-716.5K-$-410.18K
Operating cash flow$1.65M-$-490K$830K-$-3.23M-$-1.42M
Capital expenditure$0.00-$-60K-$-70K-$-140K-$-40K
Free cash flow$1.65M-$-550K$750K-$-3.37M-$-1.45M
Total assets$13.6M$11.2M$11.9M$11M$17.7M
Total debt$1.06M$1.41M$1.84M$1.09M$1M
Net debt-$-4.34M-$-2.35M-$-2.47M-$-2.54M-$-5.97M
Total equity$10.2M$8.59M$8.36M$8.88M$14.8M
Cash and short-term investments$5.4M$3.76M$4.31M$3.63M$6.97M
Income statement
20252024202320222021
Revenue$18.8M$14.2M$14.2M$9.97M$10.2M
Cost of revenue$7.3M$5.44M$5.83M$5.24M$4.58M
Gross profit$11.5M$8.72M$8.4M$4.73M$5.63M
Research and development expenses$1.34M$910K$870K$1.25M$1.5M
Selling, general and administrative expenses$9M$7.68M$8.91M$7.59M$7.2M
Other expenses$0.00$140K$210K$220K$190K
Operating expenses$10.3M$8.72M$10M$9.07M$8.88M
Cost and expenses$17.6M$14.2M$15.8M$14.3M$13.5M
Interest income$140K$90K$60K$10K$10K
Interest expense$0.00$0.00$0.00$20K$40K
Depreciation and amortization$140K$140K$210K$570K$250K
Ebitda$1.35M$230K-$-1.36M-$-3.69M-$-2.49M
Operating income$1.15M$10K-$-1.59M-$-4.33M-$-3.25M
Total other income/expenses, net$60K$80K$20K$60K$470K
Income before tax$1.21M$90K-$-1.57M-$-4.28M-$-2.78M
Income tax expense$10K$10K$0.00$0.00$0.00
Net income$1.19M$70K-$-1.57M-$-7.38M-$-4.11M
Weighted average shares outstanding$10.6M$10.5M$10.4M$10.3M$10M
Weighted average diluted shares outstanding$11M$10.6M$10.4M$10.3M$10M
Balance sheet
20252024202320222021
Cash and short-term investments$5.4M$3.76M$4.31M$3.63M$6.97M
Net receivables$2.41M$1.78M$1.5M$1.29M$1.64M
Inventory$3.23M$2.62M$2.47M$3.15M$4.46M
Total current assets$11.2M$8.3M$8.4M$8.26M$13.6M
Property, plant and equipment, net$1.13M$1.54M$1.96M$1.1M$690K
Goodwill and intangible assets$1.08M$1.32M$1.41M$1.58M$1.76M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.42M$2.91M$3.46M$2.74M$4.02M
Total assets$13.6M$11.2M$11.9M$11M$17.7M
Accounts payable$910K$650K$870K$740K$1.33M
Short-term debt$390K$350K$450K$390K$560K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.77M$1.56M$2.11M$1.41M$2.39M
Long-term debt$670K$1.06M$1.39M$710K$440K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$670K$1.06M$1.39M$710K$510K
Capital lease obligations$670K$1.41M$1.84M$1.02M$650K
Total liabilities$3.44M$2.62M$3.5M$2.12M$2.9M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-143.14M-$-144.33M-$-144.41M-$-142.83M-$-135.72M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$60K
Total equity$10.2M$8.59M$8.36M$8.88M$14.8M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$1.06M$1.41M$1.84M$1.09M$1M
Net debt-$-4.34M-$-2.35M-$-2.47M-$-2.54M-$-5.97M
Cash flow statement
20252024202320222021
Net income$1.19M$70K-$-1.57M-$-4.55M-$-3.87M
Depreciation and amortization$140K$140K$210K$350K$250K
Stock-based compensation$300K$150K$1.05M$950K$1.26M
Change in working capital-$-410K-$-1.55M$490K$230K$880K
Accounts receivable-$-630K-$-280K-$-220K$360K-$-280K
Inventory-$-690K-$-410K$390K$920K$300K
Accounts payable$260K-$-220K$130K-$-590K$910K
Net cash provided by operating activities$1.65M-$-490K$830K-$-3.23M-$-1.42M
Investments in property, plant and equipment$0.00-$-60K-$-70K-$-140K-$-40K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00-$-50K-$-70K-$-140K-$-90K
Common stock issued$0.00$0.00$0.00$160K$500K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-10K-$-10K-$-80K$30K$240K
Net change in cash$1.64M-$-550K$670K-$-3.34M-$-1.28M
Cash at end of period$5.4M$3.76M$4.31M$3.63M$6.97M
Operating cash flow$1.65M-$-490K$830K-$-3.23M-$-1.42M
Capital expenditure$0.00-$-60K-$-70K-$-140K-$-40K
Free cash flow$1.65M-$-550K$750K-$-3.37M-$-1.45M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Nephros, Inc.

        Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.

        CEO
        Robert Banks
        Employees
        36
        Beta
        1.49

        Explore

        Frequently asked questions

        What is the intrinsic value of Nephros, Inc. (NEPH)?

        InvestorsCraft does not currently publish an intrinsic value for NEPH. How the IC value is calculated.

        Is NEPH undervalued?

        InvestorsCraft does not publish an undervaluation signal for NEPH at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.